{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:17:47Z","timestamp":1791839867677,"version":"4.3.4"},"reference-count":15,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2009,11,30]],"date-time":"2009-11-30T00:00:00Z","timestamp":1259539200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2010,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> Pityriasis rubra pilaris (PRP) is a rare inflammatory dermatosis with frequent clinical presentation as erythroderma. Conventional systemic treatment is often unsatisfactory and limited by long\u2010term toxicity. The use of tumour necrosis factor (TNF) antagonists has been reported previously in single cases, but lacking long\u2010term follow\u2010up or comparison between different biological agents.<\/jats:p><jats:p><jats:bold>Objectives\u2002<\/jats:bold> To assess the long\u2010term efficacy and safety of TNF\u2010alpha antagonist, infliximab and etanercept, either in monotherapy or in combination therapy of severe, refractory adult\u2010onset PRP.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> Seven patients of adult\u2010onset PRP, six newly diagnosed type\u2010I and 1 type\u2010II, which were resistant or ineligible to conventional systemic treatment, received a single course of infliximab or etanercept therapy, alone or in combination with low\u2010dose acitretin (&gt;0.25\u2003mg\/kg\/daily). After complete remission and treatment discontinuation, a follow\u2010up period of 12\u2003months was evaluated for relapses.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Six patients obtained complete remission after a single course of anti\u2010TNF\u2010alpha therapy: mean therapy duration was 19.3\u2003weeks (range 6\u201348\u2003weeks). All patients obtained significant clearing (&gt;75% of body surface area) of skin lesions at week 12. Two patients with marked keratoderma developed localized disease recurrence during treatment. During follow\u2010up, only a single patient, affected by type II PRP, had disease relapse.<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> Both TNF\u2010alpha antagonists proved successful for the treatment of refractory, adult\u2010onset PRP, yielding complete and persistent clinical responses in type\u2010I PRP. Infliximab was associated with a more rapid onset of action, while treatment duration was comparable with etanercept. PRP type II warranted long\u2010term therapy and showed relapse after drug discontinuation.<\/jats:p>","DOI":"10.1111\/j.1468-3083.2009.03511.x","type":"journal-article","created":{"date-parts":[[2009,11,30]],"date-time":"2009-11-30T09:20:20Z","timestamp":1259572820000},"page":"881-884","source":"Crossref","is-referenced-by-count":33,"title":["Treatment of refractory adult\u2010onset pityriasis rubra pilaris with TNF\u2010alpha antagonists: a case series"],"prefix":"10.1111","volume":"24","author":[{"given":"S","family":"Garcovich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AR","family":"Di Giampetruzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Antonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Garcovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Didona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,7,2]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(08)80543-9"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-5945-5-5"},{"key":"e_1_2_7_4_2","first-page":"980","article-title":"Pityriasis rubra pilaris","volume":"55","author":"Artik S","year":"2004","journal-title":"Hautarzt"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1981.tb00946.x"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.1999.00513.x"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb01180.x"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2008.03095.x"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-0308"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08379.x"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2008.527"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.05.037"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2007.02282.x"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.143.12.1597"},{"key":"e_1_2_7_15_2","first-page":"18","article-title":"Pityriasis rubra pilaris: failure of combination treatment with acitretin and infliximab","volume":"12","author":"Lu R","year":"2006","journal-title":"Dermatol Online J"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1470.2001.01967.x"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-3083.2009.03511.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-3083.2009.03511.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T17:08:54Z","timestamp":1698944934000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-3083.2009.03511.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,2]]},"references-count":15,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["10.1111\/j.1468-3083.2009.03511.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-3083.2009.03511.x","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7,2]]}}}